Hatem A Azim1, Andrea Vingiani2, Fedro Peccatori3, Giuseppe Viale4, Sherene Loi5, Giancarlo Pruneri4. 1. BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: hatem.azim@bordet.be. 2. Division of Pathology, European Institute of Oncology, Milan, Italy. 3. Fertility and Procreation Unit, Department of Gynecology Oncology, European Institute of Oncology, Milan, Italy. 4. Division of Pathology, European Institute of Oncology, Milan, Italy; University of Milan, School of Medicine, Milan, Italy. 5. Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Abstract
BACKGROUND: Tumour infiltrating lymphocytes (TILs) is one of the most exciting breast cancer biomarkers, yet no data is available on its prevalence in tumours diagnosed during pregnancy. METHODS: We evaluated the prevalence of TILs (stromal and intratumoural) in pregnant and non-pregnant young breast cancer patients. RESULTS: 11/116 (9.6%) of the non-pregnant and 2/86 (2.3%) pregnant patients had TILs ≥ 50% (p < 0.001) with highest prevalence observed in triple negative tumours (p = 0.01). CONCLUSIONS: This is the first report on TILs in tumours diagnosed during pregnancy. The low prevalence could reflect the state of low host immunity associated with pregnancy.
BACKGROUND: Tumour infiltrating lymphocytes (TILs) is one of the most exciting breast cancer biomarkers, yet no data is available on its prevalence in tumours diagnosed during pregnancy. METHODS: We evaluated the prevalence of TILs (stromal and intratumoural) in pregnant and non-pregnant young breast cancerpatients. RESULTS: 11/116 (9.6%) of the non-pregnant and 2/86 (2.3%) pregnant patients had TILs ≥ 50% (p < 0.001) with highest prevalence observed in triple negative tumours (p = 0.01). CONCLUSIONS: This is the first report on TILs in tumours diagnosed during pregnancy. The low prevalence could reflect the state of low host immunity associated with pregnancy.
Authors: Katarzyna J Jerzak; Nechama Lipton; Sharon Nofech-Mozes; Dina Boles; Elzbieta Slodkowska; Gregory R Pond; Ellen Warner Journal: Breast Cancer Res Treat Date: 2021-07-27 Impact factor: 4.872